Clinical trials: Anti Vascular Endothelial Growth Factor
Age-Related Macular Degeneration
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related…
- Trial name
- NCT05984927
- Testing
- NG101 AAV gene therapy
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Elisigen, Inc.
Age-Related Macular Degeneration
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent…
- Trial name
- NCT02357342
- Testing
- Sirolimus, Standard of Care intravitreal injections of anti-VEGF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
AMD
Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan
Purpose To report the long-term efficacy of patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) in Changhua Christian Hospital in Taiwan.
- Trial name
- OIVAEGFFAMDIT (NCT03324542)
- Testing
- Aflibercept [Eylea]
- Where
- Taiwan
- Volunteers
- 63 people
- Sponsor
- Changhua Christian Hospital
Ophthalmology, Macular Edema
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.
- Conditions
- Ophthalmology, Macular Edema, Macular Degeneration
- Trial name
- POLARIS (NCT01771081)
- Testing
- Ranibizumab (or other DME treatment)
- Where
- 8 sites in France, Germany and 6 more
- Volunteers
- 911 people
- Sponsor
- Bayer
Cancer
Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy
We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study.
- Trial name
- NCT00786383
- Testing
- IMC-1121B, 1121B
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Neovascular Glaucoma, Neovascularization
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
The clinical trial is aimed to evaluate the anti-neovascular effect of KDR2-2 suspension eyedrop in the treatment of neovascular glaucoma.
- Trial name
- KDR-NVG (NCT04844619)
- Testing
- 4mg/ml KDR2-2 suspension eyedrop, 16mg/ml KDR2-2 suspension eyedrop
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Macular Disease
Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab, ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular disease.
- Trial name
- NCT01994174
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Nebraska
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in…
- Trial name
- DAZZLE (NCT04049266)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Czechia and 5 more
- Volunteers
- 559 people
- Sponsor
- Kodiak Sciences Inc
Branch Retinal Vein Occlusion
Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion
Retinal vein occlusion (RVO) is the second leading cause of retinal vascular disease in patients older than 50 years.The prevalence varies from 0.7% to 1.6% in the literature.
- Trial name
- NCT02033031
- Testing
- Lucentis intravitreal injection, Avastin intravitreal injection
- Where
- Austria
- Volunteers
- 28 people
- Sponsor
- Medical University of Vienna
Multiple Myeloma, Allogeneic Stem Cell Transplantation
Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
Most patients with multiple myeloma (MM) die due to relapse resistant to current treatment, including treatment with anti-B cell maturation antigen (BCMA) CAR-T cells.
- Trial name
- CARTemis-1 (NCT05982275)
- Testing
- CARTemis-1
- Where
- 5 sites in Spain
- Volunteers
- 25 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Age-Related Macular Degeneration (AMD), Macular Degeneration
X-82 to Treat Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
- Conditions
- Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD
- Trial name
- NCT02348359
- Testing
- X-82, Anti-VEGF
- Where
- 35 sites in United States
- Volunteers
- 157 people
- Sponsor
- Tyrogenex
Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth…
- Conditions
- Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT05110118
- Testing
- LY01008, Avastin
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Diabetic Macular Edema, Cataract
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs.
- Trial name
- STAMP (NCT03832179)
- Testing
- Bevacizumab, Ranibizumab, Aflibercept
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bay Area Retina Associates
Neovascular Age-Related Macular Degeneration
Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD
Neovascular Age-Related Macular Degeneration (NV AMD) remains the leading cause of vision loss among people over 65. Intravitreal injections with drugs that block VEGF have revolutionized treatment of NV AMD.
- Trial name
- NCT02367365
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Duke University
Hepatocellular Carcinoma (HCC)
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma with…
- Trial name
- NCT06881446
- Where
- China
- Volunteers
- 2,651 people
- Sponsor
- Zhongda Hospital
Branch Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
- Trial name
- RAPTOR (NCT03802630)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 102 sites in United States, Austria and 17 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
Laser photocoagulation and intravitreal anti-vascular growth factor injections are commonly used treatment options for individuals with diabetic macular edema.
- Trial name
- DIME (NCT02471651)
- Testing
- Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- California Retina Consultants
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
A previous pilot study demonstrated that commonly available glaucoma drops (dorzolamide-timolol) might decrease the amount of chronic swelling in patient with wet age-related macular degeneration who have been receiving…
- Trial name
- DAWN (NCT03034772)
- Testing
- Dorzolamide-timolol, Artificial tears
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Wills Eye
Cancer, Colon Cancer
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever
- Trial name
- NCT00911170
- Testing
- Pegfilgrastim, Bevacizumab, Standard Chemotherapy
- Where
- 154 sites in United States, Australia and 15 more
- Volunteers
- 847 people
- Sponsor
- Amgen
Neovascular Age Related Macular Degeneration (AMD), Open Angle Glaucoma
TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection
This is a prospective, open label study assessing the 24-hour IOP patterns using TF in patients undergoing anti-VEGF injection for the treatment of neovascular AMD (age related macular degeneration).
- Trial name
- NCT01983579
- Testing
- Intraocular anti-VEGF injection, SENSIMED Triggerfish
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Sensimed AG